Dr. Djaballah has significant industrial experience
in preclinical drug discovery, gained over the years in pharmaceutical and biotechnology companies.
Carter and his colleagues set up Avalon to aggressively tackle harnessing genomic information to speed up
the preclinical drug discovery process.
The journal covers the whole of
the preclinical drug discovery process, from target identification and validation, through hit identification, lead identification and optimisation, though to candidate selection.